328 related articles for article (PubMed ID: 27413017)
1. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.
van Dalem J; Brouwers MC; Stehouwer CD; Krings A; Leufkens HG; Driessen JH; de Vries F; Burden AM
BMJ; 2016 Jul; 354():i3625. PubMed ID: 27413017
[TBL] [Abstract][Full Text] [Related]
2. The association between adherence to oral anti-diabetic drugs and hypoglycaemia in persons with Type 2 diabetes.
Quilliam BJ; Ozbay AB; Sill BE; Kogut SJ
Diabet Med; 2013 Nov; 30(11):1305-13. PubMed ID: 23586474
[TBL] [Abstract][Full Text] [Related]
3. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study.
Gulliford M; Latinovic R
Diabetes Metab Res Rev; 2004; 20(3):239-45. PubMed ID: 15133756
[TBL] [Abstract][Full Text] [Related]
4. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.
Bannister CA; Holden SE; Jenkins-Jones S; Morgan CL; Halcox JP; Schernthaner G; Mukherjee J; Currie CJ
Diabetes Obes Metab; 2014 Nov; 16(11):1165-73. PubMed ID: 25041462
[TBL] [Abstract][Full Text] [Related]
5. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK--a nested case-control analysis.
Bruderer SG; Bodmer M; Jick SS; Bader G; Schlienger RG; Meier CR
Diabetes Obes Metab; 2014 Sep; 16(9):801-11. PubMed ID: 24612200
[TBL] [Abstract][Full Text] [Related]
6. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
[TBL] [Abstract][Full Text] [Related]
7. Sulphonylureas versus metformin and the risk of ventricular arrhythmias among people with type 2 diabetes: A population-based cohort study.
Islam N; Reynier P; Douros A; Yu OHY; Filion KB
Diabetes Obes Metab; 2023 Jun; 25(6):1523-1533. PubMed ID: 36722703
[TBL] [Abstract][Full Text] [Related]
8. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
[TBL] [Abstract][Full Text] [Related]
9. Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care.
Hippisley-Cox J; Coupland C
BMJ; 2016 Mar; 352():i1450. PubMed ID: 27029547
[TBL] [Abstract][Full Text] [Related]
10. Metformin and the sulphonylureas: the comparative risk.
Campbell IW
Horm Metab Res Suppl; 1985; 15():105-11. PubMed ID: 3935560
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
Vexiau P; Mavros P; Krishnarajah G; Lyu R; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():16-24. PubMed ID: 18435670
[TBL] [Abstract][Full Text] [Related]
12. Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study.
van Dalem J; Brouwers MCGJ; Stehouwer CDA; Krings A; Klungel OH; Driessen JHM; de Vries F; Burden AM
Diabetes Obes Metab; 2018 Apr; 20(4):1056-1060. PubMed ID: 29171906
[TBL] [Abstract][Full Text] [Related]
13. Progression to insulin therapy among patients with type 2 diabetes treated with sitagliptin or sulphonylurea plus metformin dual therapy.
Inzucchi SE; Tunceli K; Qiu Y; Rajpathak S; Brodovicz KG; Engel SS; Mavros P; Radican L; Brudi P; Li Z; Fan CP; Hanna B; Tang J; Blonde L
Diabetes Obes Metab; 2015 Oct; 17(10):956-64. PubMed ID: 25962401
[TBL] [Abstract][Full Text] [Related]
14. Hypoglycaemia when adding sulphonylurea to metformin: a systematic review and network meta-analysis.
Andersen SE; Christensen M
Br J Clin Pharmacol; 2016 Nov; 82(5):1291-1302. PubMed ID: 27426428
[TBL] [Abstract][Full Text] [Related]
15. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
BMJ; 2016 May; 353():i2231. PubMed ID: 27142267
[TBL] [Abstract][Full Text] [Related]
16. Association between first-line monotherapy with sulphonylurea versus metformin and risk of all-cause mortality and cardiovascular events: a retrospective, observational study.
Morgan CL; Mukherjee J; Jenkins-Jones S; Holden SE; Currie CJ
Diabetes Obes Metab; 2014 Oct; 16(10):957-62. PubMed ID: 24720708
[TBL] [Abstract][Full Text] [Related]
17. Mortality risk with sulphonylureas compared to metformin.
Holden SE; Currie CJ
Diabetes Obes Metab; 2014 Oct; 16(10):885-90. PubMed ID: 24533964
[TBL] [Abstract][Full Text] [Related]
18. Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study.
Eppenga WL; Lalmohamed A; Geerts AF; Derijks HJ; Wensing M; Egberts A; De Smet PA; de Vries F
Diabetes Care; 2014 Aug; 37(8):2218-24. PubMed ID: 24842984
[TBL] [Abstract][Full Text] [Related]
19. Switching from sulphonylurea to a sodium-glucose cotransporter2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycaemia.
Wan Seman WJ; Kori N; Rajoo S; Othman H; Mohd Noor N; Wahab NA; Sukor N; Mustafa N; Kamaruddin NA
Diabetes Obes Metab; 2016 Jun; 18(6):628-32. PubMed ID: 26889911
[TBL] [Abstract][Full Text] [Related]
20. Severe hypoglycemia is associated with antidiabetic oral treatment compared with insulin analogs in nursing home patients with type 2 diabetes and dementia: results from the DIMORA study.
Abbatecola AM; Bo M; Barbagallo M; Incalzi RA; Pilotto A; Bellelli G; Maggi S; Paolisso G;
J Am Med Dir Assoc; 2015 Apr; 16(4):349.e7-12. PubMed ID: 25669671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]